The latest biotech news

News and Trends 29 Oct 2019

MorphoSys and Galapagos’ Eczema Drug Abandoned at Phase II

Development of MorphoSys, Galapagos, and Novartis’ first-in-class antibody drug has been discontinued during a phase II trial after an interim analysis suggested it wouldn’t meet its main endpoint of reducing eczema symptoms. The drug was being developed to treat the inflammatory skin condition atopic dermatitis, also known as eczema. It arose from a collaboration between […]

October 29, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 28 Oct 2019

AI-Driven Antibiotic Susceptibility Test Launched in Austria

Ares Genetics, an Austrian subsidiary of the German Curetis Group, has launched an early access program for its AI-driven antibiotic susceptibility test. The company, which focuses on molecular diagnostics, has a large, regularly updated database of genetic information on disease-causing microbes including strains showing antimicrobial resistance. The new test uses high-resolution sequencing to gain genetic […]

October 28, 2019 - 2 minutesmins - By Helen Albert

News and Trends 25 Oct 2019

EU Court Ushers in the Use of Phages Against Listeria in Food

Amidst recent listeria outbreaks in Europe, the European Court of Justice has issued a court order in favor of the company Micreos Food Safety allowing the use of its phage technology to keep listeria at bay in food. Bacteriophages, or phages for short, are viruses that only kill specific bacterial strains and are harmless to […]

October 25, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 24 Oct 2019

British AI Firm Gets €9M Boost to Develop Drug-Discovery Tech

London-based LabGenius has secured €8.9M in Series A funding, which the company plans to use to scale up its AI- and robotics-based drug development technology. LabGenius focuses on developing protein-based therapeutics using its ‘robot scientist’ EVA. “By transforming how these drugs are discovered, we have a shot at improving the lives of countless people,” said […]

October 24, 2019 - 2 minutesmins - By Helen Albert

alzheimers disease treatment vivoryon therapeutics

News and Trends 24 Oct 2019

German Alzheimer’s Drug Backed with €43M After Biogen’s Surprise Turnaround

The German company Vivoryon Therapeutics has raised €43M on Euronext Amsterdam to fund a phase IIb trial of a drug that could slow the progression of Alzheimer’s disease by blocking toxic forms of the protein amyloid-beta. Vivoryon Therapeutics, previously known as Probiodrug, raised the money using a rights offering and a private placement on Euronext […]

October 24, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 22 Oct 2019

Austrian Biotech Will Develop Viral Protein For Vaginal Infection

The Austrian biotech company PhagoMed Biopharma is developing a viral protein that could one day treat the common condition bacterial vaginosis without disrupting the microbiome as traditional antibiotics do. The preclinical drug candidate is derived from a protein called an endolysin. Endolysins are made by bacteria-hunting viruses called bacteriophages and kill bacteria by rupturing the […]

October 22, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 21 Oct 2019

Update: Abivax’s Ulcerative Colitis Drug Effective Long-Term

Update (21/10/2019): An extension of French biotech Abivax’s phase IIa trial shows its treatment for the inflammatory bowel disease ulcerative colitis has good efficacy after a year of treatment, with 75% of the screened patients remaining symptom-free. Of the 32 patients in the original phase IIa trial, 19 patients were treated with Abivax’s drug in […]

October 21, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 17 Oct 2019

Innate Pharma Raises €62M IPO to Develop Antibody Drugs for Cancer

The French company Innate Pharma has raised a Nasdaq IPO of €62.1M ($68.8M) to fund the development of antibody immunotherapies for solid tumors and blood cancer. Innate Pharma’s lead candidate antibody monalizumab is being co-developed in phase II with AstraZeneca for the treatment of head and neck cancer and colorectal cancer. Monalizumab is a member […]

October 17, 2019 - 2 minutesmins - By Jonathan Smith

cancer immunotherapy gammadelta therapeutics adaptate biotherapeutics

News and Trends 16 Oct 2019

GammaDelta Therapeutics Spins Out Cancer Immunotherapy Biotech

The UK biotech GammaDelta Therapeutics has founded Adaptate Biotherapeutics to develop cancer immunotherapies based on antibodies that boost a rare type of immune cell. Adaptate Biotherapeutics is a spin-out of GammaDelta Therapeutics, a London company founded in 2016 that specializes in using a rare type of immune cells, known as gamma delta T-cells, to fight […]

October 16, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 16 Oct 2019

UK Firm Raises €51M to Repurpose Drugs for Rare Diseases Using AI

The Cambridge-based artificial intelligence company Healx has raised a Series B round of €50.8M to launch an AI tool that reduces the time it takes to develop treatments for rare diseases by five years. The Series B round was led by the UK VC firm Atomico and includes the returning investor Jonathan Milner, the founder […]

October 16, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 15 Oct 2019

German Cancer Virotherapy Biotech Launches with €12M Series A

Abalos Therapeutics launches today with €12M in Series A funding to get the development of its arenavirus-based cancer therapies off the ground. Boehringer Ingelheim Venture Fund and Gründerfonds Ruhr co-led the investment round, with additional contributions from NRW.BANK and High-Tech Gründerfonds. Abalos, which is based in Essen, Germany, will focus on developing anti-cancer drugs with […]

October 15, 2019 - 2 minutesmins - By Helen Albert

20191008 Rheticus Evonik DEBO0495 freigegeben e1571095521515

News and Trends 15 Oct 2019

Artificial Photosynthesis-Driven Chemical Plant Launched in Germany

The German industrial giants Siemens and Evonik have launched a joint project to build and run a test plant to make valuable chemicals from water and waste carbon dioxide using bacteria — a process known as artificial photosynthesis. The test plant, which is currently under construction, will be based at Evonik’s site in Marl, Germany, […]

October 15, 2019 - 3 minutesmins - By Helen Albert

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

MorphoSys and Galapagos’ Eczema Drug Abandoned at Phase II

AI-Driven Antibiotic Susceptibility Test Launched in Austria

EU Court Ushers in the Use of Phages Against Listeria in Food

British AI Firm Gets €9M Boost to Develop Drug-Discovery Tech

German Alzheimer’s Drug Backed with €43M After Biogen’s Surprise Turnaround

Austrian Biotech Will Develop Viral Protein For Vaginal Infection

Update: Abivax’s Ulcerative Colitis Drug Effective Long-Term

Innate Pharma Raises €62M IPO to Develop Antibody Drugs for Cancer

GammaDelta Therapeutics Spins Out Cancer Immunotherapy Biotech

UK Firm Raises €51M to Repurpose Drugs for Rare Diseases Using AI

German Cancer Virotherapy Biotech Launches with €12M Series A

Artificial Photosynthesis-Driven Chemical Plant Launched in Germany

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!